John McLaughlin
Director/Board Member chez PDL BIOPHARMA, INC.
Fortune : 150 633 $ au 31/03/2024
Profil
John Peter McLaughlin was the founder of PEAK Surgical, Inc. (founded in 2005) and held the title of Director.
He is also the founder of Oldtech, Inc. Mr. McLaughlin's current job(s) include being a Director at PDL BioPharma, Inc. (since 2008) and a Director at Noden Pharma DAC.
Mr. McLaughlin's former job(s) include being the Chief Executive Officer & Director at Anesiva, Inc. (from 2000 to 2008), Chairman at Rockwell Medical, Inc. (from 2019 to 2022), Independent Director at Seagen Inc. (from 2007 to 2016), Independent Director at LENSAR, Inc. (from 2017 to 2023), Director at IDEC Pharmaceuticals Corp., Director at Axogen, Inc. (from 2012 to 2014), Independent Director at Adverum Biotechnologies, Inc. (from 2014 to 2016), Director at Noden Pharma USA, Inc., and Legal Counsel at U.S.
House of Representatives.
Mr. McLaughlin's education includes an undergraduate degree from the University of Notre Dame and a graduate degree from The Catholic University of America.
Mr. McLaughlin is also the founder of Oldtech, Inc...
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LENSAR INC
0,39% | 02/06/2023 | 44 343 ( 0,39% ) | 150 633 $ | 31/03/2024 |
Postes actifs de John McLaughlin
| Sociétés | Poste | Début |
|---|---|---|
| PDL BIOPHARMA, INC. | Director/Board Member | 01/10/2008 |
Noden Pharma DAC
 Noden Pharma DAC Pharmaceuticals: MajorHealth Technology Noden Pharma DAC is a pharmaceutical company, which engages in the acquisition of prescription medicines across a range of therapeutic areas. It manufactures, markets, and sells Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor, for the treatment of hypertension. The company is headquartered in Dublin, Ireland. | Director/Board Member | - |
Anciens postes connus de John McLaughlin
| Sociétés | Poste | Fin |
|---|---|---|
| LENSAR, INC. | Director/Board Member | 31/10/2023 |
| ROCKWELL MEDICAL, INC. | Chairman | 01/04/2022 |
| SEAGEN INC. | Director/Board Member | 16/12/2016 |
| ADVERUM BIOTECHNOLOGIES, INC. | Director/Board Member | 31/08/2016 |
| AXOGEN, INC. | Director/Board Member | 20/08/2014 |
Formation de John McLaughlin
| University of Notre Dame | Undergraduate Degree |
| The Catholic University of America | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ROCKWELL MEDICAL, INC. | Health Technology |
| LENSAR, INC. | Health Technology |
| AXOGEN, INC. | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Anesiva, Inc.
 Anesiva, Inc. Pharmaceuticals: MajorHealth Technology Anesiva, Inc. develops and markets therapeutic drugs. Anesiva is a biopharmaceutical company focused on the development and commercialization of novel pharmaceutical products for pain management. The firm was founded in 1999 and is headquartered in San Francisco, CA. | Health Technology |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
PEAK Surgical, Inc.
 PEAK Surgical, Inc. Medical SpecialtiesHealth Technology PEAK Surgical is a medical device company that has developed the PEAK Surgery System, a new tissue dissection system based on a proprietary technology that represents an important advance in radiofrequency surgical technologies. The PEAK Surgery System consists of the PEAK PlasmaBlade, a family of disposable cutting devices that offer the exacting control of a scalpel and the bleeding control of traditional electrosurgery without extensive collateral damage, and the PULSAR Generator, which supplies pulsed plasma radiofrequency energy to the PlasmaBlade. The PEAK Surgery System is cleared for use in general, plastic and reconstructive, ENT, gynecologic, orthopedic, arthroscopic, spinal and neurological surgical procedures in the United States, and for use in general surgery in the European Union. It was launched in the United States in July 2008 and has been used by U.S. surgeons on many patients, including general, gynecologic, orthopedic and plastic and reconstructive surgeries | Health Technology |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
| U.S. House of Representatives | Government |
Noden Pharma DAC
Noden Pharma DAC Pharmaceuticals: MajorHealth Technology Noden Pharma DAC is a pharmaceutical company, which engages in the acquisition of prescription medicines across a range of therapeutic areas. It manufactures, markets, and sells Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor, for the treatment of hypertension. The company is headquartered in Dublin, Ireland. | Health Technology |
Noden Pharma USA, Inc.
 Noden Pharma USA, Inc. Electronic Equipment/InstrumentsElectronic Technology Noden Pharma USA, Inc. is engaged in manufacturing and commercialization of filled and finished medicine products. The company is headquartered in Orlando, FL. | Electronic Technology |
